Johnson & Johnson (JNJ) Offering Possible 12.36% Return Over the Next 9 Calendar Days

Johnson & Johnson's most recent trend suggests a bearish bias. One trading opportunity on Johnson & Johnson is a Bear Call Spread using a strike $160.00 short call and a strike $165.00 long call offers a potential 12.36% return on risk over the next 9 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $160.00 by expiration. The full premium credit of $0.55 would be kept by the premium seller. The risk of $4.45 would be incurred if the stock rose above the $165.00 long call strike price.

The 5-day moving average is moving down which suggests that the short-term momentum for Johnson & Johnson is bearish and the probability of a decline in share price is higher if the stock starts trending.

The 20-day moving average is moving down which suggests that the medium-term momentum for Johnson & Johnson is bearish.

The RSI indicator is at 34.04 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here

LATEST NEWS for Johnson & Johnson

Russia Secures Sputnik Italy Output in European Vaccine Push
Tue, 09 Mar 2021 09:49:38 +0000
(Bloomberg) — Russia is pushing ahead with plans to make its Covid-19 vaccine in Europe, securing a deal to produce the Sputnik V shot in Italy and discussing production in Germany and France.Adienne Pharma & Biotech SA signed an agreement to manufacture the vaccine at its production site in the Milan region, Antonio Francesco Di Naro — the founder and president of the Lugano, Switzerland-based company — told Bloomberg in an interview.The deal with Russia’s sovereign wealth fund RDIF is the first European production deal for the vaccine. While Russia was first to approve a shot for the general public and promoted it as a way to help end the pandemic globally, it has been slower than some rivals to scale up output.The vaccine is under review by authorities in the European Union, which has struggled to ramp up inoculations amid a lack of supply. The sluggish rollout has prodded some countries to consider their own purchasing deals in a challenge to the bloc’s solidarity.“There are many Italian regions which are enthusiastic about having Sputnik, they would also want to produce it,” Kirill Dmitriev, chief executive officer of the state-run Russian Direct Investment Fund, told Italian Rai3 television on Sunday. “We have a partnership in Germany. We’re talking to several French companies.”Sputnik V’s developers have had contact with German vaccine maker IDT Biologika GmbH, according to IDT spokesman Ulrich Gartner, who confirmed a report by German broadcaster MDR. He said that the company cannot comment on the details of ongoing talks with potential customers.IDT, based in the state of Saxony-Anhalt, signed a letter of intent last month to help AstraZeneca Plc boost supply of its vaccine.Dmitriev, who is in charge of Sputnik’s international roll-out and backed its development, said in the Italian TV interview that production in the country could start in June. The timing depends on approval from Italian regulators, and Di Naro said he couldn’t set production targets as of now.The deal comes as Prime Minister Mario Draghi pledged to speed up Italy’s fledgling vaccination campaign amid a new rise in infections from the disease that’s led to more than 100,000 fatalities in the country.Draghi blocked the export of AstraZeneca’s vaccine earlier this month after the company sharply reduced planned deliveries to the EU. He was the first European leader to use the recently-introduced powers, highlighting the sensitivity in the region over the supply of Covid-19 shots.European Commission President Ursula von der Leyen on Monday lashed out at manufacturers for failing to uphold their commitments as countries in Europe struggle to step up the pace of inoculations.Officials are also bracing for delays in the delivery of a new vaccine from Johnson & Johnson, according to two people with knowledge of the process.The shots, which are due to be approved by the European Medicines Agency this week, were due to start arriving at the beginning of April but now aren’t expected until the middle of the month at the earliest, one of the officials said.The EU has administered 9.35 doses per 100 people, compared with nearly 28 for the U.S. and more than 35 for the U.K., according to Bloomberg’s Coronavirus Vaccine Tracker.The European Medicines Agency said March 4 that it started a rolling review of Sputnik V to test compliance with safety and quality standards, the first major step in gaining approval for use in the European Union. The Russian vaccine started to gain broader international recognition after The Lancet medical journal published peer-reviewed results of interim trials showing 91.6% efficacy.Despite the progress, it’s unclear what role political tension would play in the distribution of the Sputnik vaccine in Europe. Tensions between Russia and the EU have deteriorated further in recent months, especially after the jailing of opposition leader Alexey Navalny.In a sign of the tensions, the shot’s developer took to Twitter to demand an apology from an EMA official over comments that “raise serious questions about possible political interference” in the agency’s review.Christa Wirthumer-Hoche, EMA’s management board chairwoman, told Austrian broadcaster ORF late Sunday that national emergency authorizations are like “Russian roulette.”Pfizer Vaccine Beats Variants; Global Cases Rise: Virus Update(Updates with IDT spokesman, detail on J&J vaccine from sixth paragraph)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.

Johnson & Johnson (JNJ) Gains As Market Dips: What You Should Know
Mon, 08 Mar 2021 22:45:10 +0000
Johnson & Johnson (JNJ) closed the most recent trading day at $157.40, moving +0.83% from the previous trading session.

‘Trust is an underlying issue’ in families of color sending children back to school: CEO of Baltimore City Public Schools
Mon, 08 Mar 2021 20:34:35 +0000
Dr. Sonja Santelises, CEO of Baltimore City Public Schools, joins Yahoo Finance’s Alexis Christoforous and Akiko Fujita to discuss the push to reopen schools and women in education.

Momentum ETFs to Gain From the New Stimulus Optimism
Mon, 08 Mar 2021 20:00:08 +0000
Here we highlight some momentum ETFs that are lucrative investment picks keeping in mind the optimism surrounding Wall Street.

Fmr. White House Doctor: It’s ‘ill advised’ to relax COVID-19 mandates amid spreading variants
Mon, 08 Mar 2021 19:03:23 +0000
Dr. Jennifer Pena, Nurx Chief Medical Officer & Former White House Medical Unit Physician for Obama, Biden and Pence, joins Yahoo Finance’s Julie Hyman and Alexis Christoforous to discuss the latest coronavirus updates and women in medicine.

Related Posts

 

MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.


This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.


The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.


The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.